The Bcl-2 family proteins play an important role in maintaining myeloma cell survival and in the development of resistance to treatment. A small molecular compound, ABT-737, has been described recently as a specific inhibitor of Bcl-2 and Bcl-XL. In this study, we will: 1) Investigate the effectiveness of ABT-737 in inducing myeloma cell death in test tubes and in animal models; 2) Study the effectiveness of combination therapy of ABT-737 with other anti-myeloma drugs; 3) Investigate ABT-737’s mechanism of action. The goal of this study is to develop ABT-737 as a drug in treatment of multiple myeloma.